Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor [multiple letters] [1]

G. J. Peters*, C. J. van Groeningen, G. Giaccone, J. White R.M.

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademic

11 Citations (Scopus)
Original languageEnglish
Pages (from-to)4267-4269
JournalJournal of clinical oncology
Volume19
Issue number22
DOIs
Publication statusPublished - 15 Nov 2001
Externally publishedYes

Cite this